Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Thrombocytosis 1Thrombocythemia, Essential 1Rhabdomyosarcoma 1Recurrence 1Primary Myelofibrosis 1Polycythemia Vera 1Pancreatic Diseases 1Neuroblastoma 1Myeloproliferative Disorders 1Medulloblastoma 1Hepatoblastoma 1Hemorrhagic Disorders 1Hematologic Diseases 1Glioma 1Carcinoma 1Bone Marrow Diseases 1Blood Platelet Disorders 1Blood Coagulation Disorders 1Astrocytoma 1

Interventions

Peripheral Blood Stem Cell Transplantation 10Azacitidine 10fludarabine phosphate 8Whole-Body Irradiation 8Cyclosporine 7ruxolitinib 6Mycophenolic Acid 6Busulfan 6Methotrexate 5Cyclophosphamide 5fludarabine 4Tacrolimus 4Filgrastim 4Cytarabine 4Antilymphocyte Serum 3Alemtuzumab 311-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 3venetoclax 2eprenetapopt 2Stem Cell Transplantation 2Sirolimus 2Melphalan 2Granulocyte Colony-Stimulating Factor 2Gemcitabine 2Docetaxel 2Cord Blood Stem Cell Transplantation 2tipifarnib 1sonidegib 1rucaparib 1quizartinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Myeloproliferative Disorders × sonidegib × Clear all
NCT01787552 2020-04-15

A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF

Novartis

Phase 1/2 Completed
50 enrolled 23 charts
Myeloid

Blood Coagulation Disorders, Blood Platelet Disorders, Bone Marrow Diseases, Hematologic Diseases, Hemorrhagic Disorders, Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Thrombocytosis, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡